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Abstract
Aim: To evaluate changes in prevalence of an epidemic strain of Pseudomonas aeruginosa (AES-1, Australian epidemic strain, type 1) in a pae-
diatric cystic ﬁbrosis (CF) centre practising cohort segregation, to describe the patients' clinical characteristics at acquisition and observe mortality
rates.
Methods: Cohort segregation was introduced in our paediatric CF clinic January 2000. The prevalence of AES-1 was analysed in 1999, 2002
and 2007. Age at acquisition, lung function, presence of bronchiectasis, hospitalisations, prior P. aeruginosa infection and mortality rates
were collected. AES-1 infection was determined by pulse-ﬁeld-gel-electrophoresis (PFGE) on airway specimen cultures taken three
monthly.
Results: The prevalence of AES-1 declined from 21% in 1999 to 14% in 2002 (risk difference 7% (95% CI 1,13) p=0.0256) and to 6% in 2007
(risk difference 8% (95% CI 3,13) p=0.0018). New acquisitions after the introduction of cohort segregation were uncommon (10 by 2002 and
another 7 by 2007) with a declining incidence of 3.3 cases/year (1999 to 2002) compared to 1.4 cases/year (2002 to 2007). Twenty-two of 32
(69%) deaths between 1999 and 2007 occurred in patients infected with AES-1.
Conclusion: Cohort segregation has been associated with reductions in the prevalence of AES-1 in our CF clinic. Mortality was higher in patients
infected with AES-1 than other organisms.
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Chronic pulmonary infection with P. aeruginosa in patients
with cystic fibrosis (CF) is associated with increased morbidity
and mortality [1–3]. Person-to-person transmission of P. aerugi-
nosa epidemic strains have been demonstrated by molecular typ-
ing in CF siblings [4], and from unrelated CF patients attending
the same clinic [4–6]. We identified AES-1 in our CF clinic in
1999, and responded by introducing cohort segregation [4].⁎ Corresponding author. Tel.: +61 404866909.
E-mail address: mandie.grifﬁths@rch.org.au (A.L. Grifﬁths).
1569-1993/$ - see front matter © 2011 European Cystic Fibrosis Society. Published
doi:10.1016/j.jcf.2011.08.005Patients were grouped into cohorts using sputum culture and
PFGE. They were seen as outpatients on cohort specific days
and separated as in-patients by cohort. We reinforced standard in-
fection control measures [7–10]. Three years after initiation of
cohort segregation the prevalence of AES-1 declined [10].
The aims of this study were to evaluate the ongoing change
in prevalence of AES-1 after cohort segregation, to describe pa-
tient characteristics at acquisition and mortality rates of those
infected.by Elsevier B.V. All rights reserved.
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Fig. 1. The prevalence of AES-1 within our CF clinic in 1999, 2002 and 2007 is
shown.
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2.1. Setting
The CF clinic at the Royal Children's Hospital (RCH),
Melbourne, managed 277 (123 females) children aged 2 months
to 19 years and 5 months with CF in 2007. Most (95%) were di-
agnosed by newborn screening [11]. Patients are reviewed every
2 to 3 months with sputum or cough swab specimens each visit.
Patients under 6 years were enrolled in a randomised controlled
trial of broncho-alveolar lavage (BAL) guided therapy (1999–
2005) [12,13] or the AREST CF programme (www.ARESTCF.
com.au) which included broncho-alveolar lavage (BAL) soon
after diagnosis and annually. Patients with new P. aeruginosa ac-
quisition underwent eradication involving 2 weeks of intrave-
nous antibiotics then 3 months of twice daily nebulised
tobramycin with twice daily ciprofloxacin (months one and
three).
Cohorts were established in January 2000: P. aeruginosa nega-
tive,P. aeruginosa positive (non-epidemic),P. aeruginosaAES-1,
B. Cepacia complex and Methicillin Resistant Staphylococcus
Aureus (MRSA). Separation of cohorts was maintained at outpa-
tient visits and during hospital admissions (including the physio-
therapy department, pulmonary function laboratory, communal
areas such as patient kitchen and activity rooms). We discouraged
mixing between cohort members within and outside the hospital.
This approach was met positively by CF families [14].
2.2. Microbiology
Sputum samples were plated onto selective media by standard
techniques [15]. Antibiotic susceptibility of P. aeruginosa was
performed by disc diffusion to five antibiotic classes (beta-lactams,
beta-lactam and inhibitor combination, aminoglycosides, mono-
bactams, fluoroquinolones) [16]. Multi-drug resistance was de-
fined as resistance to all agents within two of the following
classes: beta-lactams, aminoglycosides and fluoroquinolones
[5,17]. Pulsed-field-gel-electrophoresis (PFGE) was used to iden-
tify AES-1 [5,18,19]. Isolates demonstrating identical patterns to
AES-1 on restriction fragment analysis were considered same
strain, those differing by one to three bands were considered close-
ly related strains arising from the same clone, and isolates differing
by more than four bands were considered unrelated strains [20].
2.3. Data collection and analysis
The RCH CF clinic database includes airway microbiology
results. The number of patients with AES-1 was ascertained
in 1999, before cohort segregation (baseline) and yearly until
September 2007. Data were stored in an electronic database
and analysed using Stata version 10.0 (Stata corporation,
Texas). The prevalence in 1999, 2002 and 2007 was calculated
and difference in prevalence between different periods (risk dif-
ference) was described. The 95% confidence interval of the dif-
ference was estimated and statistical significance assessed by
Fisher's exact test. The incidence of acquisition 1999–2002
and 2002–2007 were also compared.We reviewed the case records of patients who acquired
AES-1 since 1999 to identify factors associated with acquisi-
tion: sex, age at acquisition, number of hospital inpatient days
12 months before acquisition, evidence of bronchiectasis (CT
scan), pre-existing P. aeruginosa infection and best FEV1 in
the 12 months before AES-1 acquisition. Mortality data for
the whole CF clinic from 1999 to 2007 was collected.
The studywas approved by the RCHEthics in HumanResearch
Committee as a clinical audit (approval number CA28091).
3. Results
3.1. Cross-sectional and longitudinal analysis
The number of CF patients in each of the key years was: 325
(1999), 291 (2002) and 277 (2007). The prevalence of AES-1
was 67/325 (21%) in 1999, 40/291 (14%) in 2002 and 16/277
(6%) in 2007 (Fig. 1.). The reduction in prevalence correlated
with a risk difference between 1999 and 2002 of 7% (95% CI 1,
13), p=0.0256, and 8% (95% CI 3.13) p=0.0018 between 2002
and 2007, using Fisher's exact test. Ten new cases of AES-1
were identified in the period 1999 to 2002 (3.3 cases/year), and
seven new cases between 2002 and 2007 (1.4 cases/year).
Of 17 new AES-1 infections (1999–2007), the median age
at acquisition was 12 years (range 8–19 years) and 12/17
(71%) female. The mean FEV1 (% predicted) in the 12 months
before acquisition was 73% (range 34%–109%). Prior to acqui-
sition 15/17 (88%) had radiologically proven bronchiectasis. 11
of the 17 patients were hospitalised in our centre in 12 months
before acquisition (median duration 9 days, range 0–73) and all
attended outpatient clinics. 16 of 17 patients had previous in-
fection with non-epidemic P. aeruginosa (n=15) or B. Cepacia
complex (n=1) at the time of acquisition.
3.2. Mortality rates
There were 22 deaths between 1999 and 2002 (mortality rate
2.4 per 100 patients), 14 (64%) had AES-1. There were 10
deaths between 2003 and 2007 (mortality rate 0.7 per 100 pa-
tients), 8 (80%) were infected with AES-1. Over the study, 22
of 32 (69%) deaths occurred in patients infected with AES-1,
whilst the prevalence of infection within the CF clinic declined
from 21% to 6% (Fig. 2).
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We have demonstrated a significant reduction in the preva-
lence of AES-1 over the 8 years since the introduction of cohort
segregation. Most CF patients who acquired AES-1 during the
study period had established lung disease and were infected
with non-epidemic P. aeruginosa or B. cepacia complex prior
to acquisition. AES-1 was associated with the majority of
deaths in the CF clinic during this period. Interruption of its
transmission was associated with a significant reduction in
mortality within the CF clinic.
Our infection control practices follow Australian [21] and
international guidelines [7–9], which recommend segregation
of P. aeruginosa positive patients from those who are negative.
The Australian guidelines also support cohort segregation using
molecular typing. The relatively high prevalence of AES-1 in
our clinic at baseline (1999) supports the hypothesis that epi-
demic strains are more transmissible [22–24]. Whilst the effica-
cy of isolation measures in preventing transmission of respiratory
pathogens in CF remains unproven, other observational studies
indicate their importance [25,26]. There is no data to compare
the efficacy of individual isolation compared with cohort segre-
gation. The decline in prevalence of AES-1 in our clinic provides
support for cohort segregation as an effective approach to cross
infection.
The reasons for new AES-1 acquisition despite cohort segre-
gation are speculative. Infection may have occurred prior to the
introduction of cohort segregation. There may have been a
breakdown in infection control practices within, or outside,
the hospital. A common environmental source is unlikely and
has been addressed in our institution [5].
AES-1 was isolated more frequently from females with pre-
existing lung disease and prior infection with non-epidemic
P. aeruginosa. A multi-centre, 5-year prospective trial in
Australian CF centres is currently examining epidemic strains0
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Fig. 2. This figure shows the absolute number of deaths per year in the cystic
fibrosis clinic. Complete vertical bar correlates with total number of deaths
for each corresponding year. Dark segment of bar relates to proportion of pa-
tients infected with AES-1.of P. aeruginosa to characterise risk factors for, and morbidity
associated with, acquisition of epidemic strains [22].
There are some limitations to this study. A number of changes
in practice were instituted contemporaneously in our hospital. A
change in hand-washing practices from chlorhexidine solution
and water for 2 min to alcohol-based hand-wash occurred in
2006 but is unlikely to have impacted on the study results.
Most significant was the introduction of a P. aeruginosa eradica-
tion regimen after initial detection. This approach is associated
with a 90% clearance rate in our clinic (unpublished data, in-
cludes all age groups) and supported by the AREST CF data in
children under 6 years from Melbourne and Perth, Australia
(88% eradication) [27]. None of the patients in our study were in-
fants or young children b8 years, suggesting that cohort segrega-
tion and outpatient education may have been beneficial with
regard to protection from acquisition of AES-1. Furthermore,
given that prior infection with P. aeruginosa was a key risk
factor for AES-1 acquisition, it is possible that the practice of
P. aeruginosa eradication has had some influence on AES-1
acquisition.
This study highlights the value of molecular surveillance
techniques to identify and limit the spread of AES-1. We now
provide fresh evidence to suggest increased mortality associat-
ed with AES-1. We therefore continue to recommend a policy
of strict cohort segregation for patients infected with epidemic
strains of P. aeruginosa.Conﬂicts of interest
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